Armis Biopharma Announces Receipt of a $20.3 Million Contract with the Defense Threat Reduction Agency to Develop Veriox® DECON for Battlefield Wounds
/PRNewswire/ -- Armis Biopharma, Inc. announced today that the company received a $20.3 million contract from the Defense Threat Reduction Agency (DTRA) to...
Source: prnewswire.com